Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.
about
Gene therapy in Parkinson's disease: rationale and current statusUbiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunctionThe business of deubiquitination - location, location, locationThe Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord InjuryThe role of deubiquitinating enzymes in synaptic function and nervous system diseasesUbiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformationLoss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cellsA genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's diseaseExcess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1Mass spectrometry assessment of ubiquitin carboxyl-terminal hydrolase L1 partitioning between soluble and particulate brain homogenate fractionsA combination of metabolic labeling and 2D-DIGE analysis in response to a farnesyltransferase inhibitor facilitates the discovery of new prenylated proteins.Ubiquitin C-terminal hydrolase-L1 protects cystic fibrosis transmembrane conductance regulator from early stages of proteasomal degradation.Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implicationsA soluble α-synuclein construct forms a dynamic tetramer.An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes.Proteomic profiling of the epileptic dentate gyrus.Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy.Therapeutic approaches to preventing cell death in Huntington diseaseThe ubiquitin C-terminal hydrolase L1 (UCH-L1) C terminus plays a key role in protein stability, but its farnesylation is not required for membrane association in primary neurons.Genome-wide single-cell-level screen for protein abundance and localization changes in response to DNA damage in S. cerevisiae.Protein prenylation: enzymes, therapeutics, and biotechnology applications.Synaptic therapy in Alzheimer's disease: a CREB-centric approach.Serum levels of neuron-specific ubiquitin carboxyl-terminal esterase-L1 predict brain injury in a canine model of hypothermic circulatory arrest.Proteomics in neurodegenerative diseases: Methods for obtaining a closer look at the neuronal proteome.Balancing act: deubiquitinating enzymes in the nervous system.Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease.Single-residue posttranslational modification sites at the N-terminus, C-terminus or in-between: To be or not to be exposed for enzyme accessIs the amyloid hypothesis of Alzheimer's disease therapeutically relevant?Increased generation of cyclopentenone prostaglandins after brain ischemia and their role in aggregation of ubiquitinated proteins in neuronsS-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation.Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions.Regulation of proteolysis by human deubiquitinating enzymes.Identification of key genes and pathways in Parkinson's disease through integrated analysis.Nanoscale Assemblies of Small Molecules Control the Fate of CellsMechanisms of regulation and diversification of deubiquitylating enzyme function.Inhibition of UCH-L1 in oligodendroglial cells results in microtubule stabilization and prevents α-synuclein aggregate formation by activating the autophagic pathway: implications for multiple system atrophy.Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons.
P2860
Q22241423-F5C6BBF7-3DDF-48D5-8104-24C4695EACECQ26741828-48128C2B-0429-4BBB-9A30-E99865A13B71Q26766125-FACE45D7-3EA1-42F1-BBC4-02CC8E8E9871Q26767879-ECE2B90E-795A-4BD7-AF7F-0CB8C7EC686BQ26828378-024857E6-F92E-4337-A305-67487329EB08Q27661287-89CE317A-AB55-47DA-A192-9A6D47255FA0Q28118642-08B4B439-69AD-4D42-AA25-205CBADD67AEQ28485362-8DD3C176-A5E0-40E4-9EF2-85E9DD13BFA3Q28732131-ADAC6EAF-0377-48D7-81CC-0992F487E51EQ33580301-1BB533F1-FFBE-4BA5-B1B1-3DFCF9085B52Q33760617-B3D4DFFF-D854-4CBC-AF7F-1D659F0609D1Q33799710-3EBDD1F5-83F9-4C02-9B69-5CF2CB012B6EQ34012297-7B151E02-874D-47F6-BE0B-C8971776DDF6Q34050129-6D83EEE6-97B4-4769-A129-316E6065189AQ34063163-FDAC8698-2C18-400B-B8DD-ED93C63B1B82Q34183008-D094FA89-1B4E-4721-949E-60A5EE22A7C6Q34238665-31D16A67-80EF-4311-9D6B-E63050426CD5Q34411338-C117F077-7630-43AE-9F1C-8B458984AA71Q34774553-3BC8B272-A119-445A-881C-183CD9AC37BFQ34916184-2D10119B-3345-49B6-91B6-CF14F6FA32C2Q34992469-960B9977-A91D-4A70-863B-C187B72F752CQ35064948-C1DAD8D4-1A93-4E8D-861F-2301EC169A92Q35224118-DB95E192-93DD-4B87-87C6-E7BFBAB7F843Q35241298-89279EF9-B62A-405D-BDD5-2B4EE4F41D00Q35353963-B6D6910B-3615-439B-B76B-4A5ED78F23F6Q35634151-18350B4C-53C4-4C18-8463-3C4E6D1DC3E5Q35917235-7495D387-5A41-4894-8177-05653F219D2BQ36555388-2D5D8C58-8824-46C8-A5F8-9B5E81B0B5ACQ36939128-99F500FB-673E-47AC-A1BF-19A46D1F682EQ36954995-287959D9-FA0B-463C-9209-506BA5884F2FQ37704633-4A52E583-7473-41DC-80F1-6CCB23612CD7Q37853789-82CE2C5C-13A0-4D80-AE2D-1627D7A395EEQ38058956-BC9098CB-45A4-460F-A882-980F3DDAE32DQ38120938-546F4ED0-BA5B-4F90-87DB-9B665BF93984Q38430423-75A1B2FE-4522-46F3-8F4D-EDD3C84F6593Q38544296-3CD7B5C2-953F-47A0-B9BD-4D4A5171D8FBQ38687124-6674BC6D-D36D-44BA-8D8D-AD7C640033C0Q38872092-9943AFCA-B704-4242-8881-03374B165387Q38972179-E117D9F2-9738-48A2-90FF-AEB3F5EFE7DAQ38993636-1CF47F60-CF7D-4020-81A2-C67F7AC6F2B9
P2860
Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Membrane-associated farnesylat ...... arget for Parkinson's disease.
@en
Membrane-associated farnesylat ...... arget for Parkinson's disease.
@nl
type
label
Membrane-associated farnesylat ...... arget for Parkinson's disease.
@en
Membrane-associated farnesylat ...... arget for Parkinson's disease.
@nl
altLabel
Membrane-associated farnesylat ...... target for Parkinson's disease
@en
prefLabel
Membrane-associated farnesylat ...... arget for Parkinson's disease.
@en
Membrane-associated farnesylat ...... arget for Parkinson's disease.
@nl
P2093
P2860
P921
P356
P1476
Membrane-associated farnesylat ...... arget for Parkinson's disease.
@en
P2093
Peter T Lansbury
Robin K Meray
Ross A Fredenburg
Todd Logan
Tom N Grammatopoulos
Yichin Liu
Zhihua Liu
P2860
P304
P356
10.1073/PNAS.0806474106
P407
P577
2009-03-04T00:00:00Z